Serum sclerostin is an independent predictor of mortality in hemodialysis patients
Carregando...
Citações na Scopus
71
Tipo de produção
article
Data de publicação
2014
Título da Revista
ISSN da Revista
Título do Volume
Editora
BIOMED CENTRAL LTD
Citação
BMC NEPHROLOGY, v.15, article ID 190, 7p, 2014
Resumo
Background: Sclerostin (Scl) has recently emerged as a novel marker of bone remodeling and vascular calcification. However, whether high circulating Scl is also a risk factor for death is not well established. The purpose of this study was to test whether serum Scl would be associated with mortality. Methods: we measured serum Scl in a hemodialysis patients' cohort, which was followed during a ten-year period. Competing risk regression models were applied, as during the follow-up, patients were exposed to both events kidney transplant and death. Results: Ninety-one patients aged 42.3 +/- 18.8 years (55% of male gender, 15% of diabetes) were included. During the follow-up, 32 patients underwent kidney transplant and 26 patients died. Non-survivals presented higher FGF23, higher Scl and lower creatinine. There was an association between all-cause mortality and higher Scl (HR = 2.2), higher age (HR = 1.04) and presence of diabetes (HR = 2.27), by competing risk analyses. Even including potential markers of mortality, as creatinine, FGF 23, and gender, Scl, age and diabetes remained significantly related to higher mortality. Conclusion: Serum Scl is an independent predictor of mortality in dialysis patients. However, whether clinical interventions to modulate Scl would be able to improve these patients survival needs to be determined.
Palavras-chave
Sclerostin, Chronic renal failure, CKD-MBD, Hemodialysis, Mortality risk
Referências
- Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
- Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
- Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
- Brandenburg VM, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-219
- Cejka D, 2011, CLIN J AM SOC NEPHRO, V6, P877, DOI 10.2215/CJN.06550810
- Costa AG, 2014, OSTEOPOROSIS INT, V25, P1547, DOI 10.1007/s00198-014-2635-3
- de Oliveira RB, 2013, NEPHROL DIAL TRANSPL, V28, P2510, DOI 10.1093/ndt/gft234
- Ferreira JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079721
- Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
- Gooi JH, 2010, BONE, V46, P1486, DOI 10.1016/j.bone.2010.02.018
- Gutierrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130
- Kanbay M, 2012, INT UROL NEPHROL, V44, P1169, DOI 10.1007/s11255-011-0076-x
- Kidney Disease: Improving Global Outcomes CKDMBDWG, 2009, KIDNEY INT S, V113, pS1
- Klein JP, 2001, BONE MARROW TRANSPL, V28, P909, DOI 10.1038/sj.bmt.1703260
- Klein JP, 2001, BONE MARROW TRANSPL, V28, P1001, DOI 10.1038/sj.bmt.1703271
- Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428-09
- Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
- Sabbagh Y, 2012, J BONE MINER RES, V27, P1757, DOI 10.1002/jbmr.1630
- Scrucca L, 2010, BONE MARROW TRANSPL, V45, P1388, DOI 10.1038/bmt.2009.359
- Teixeira L, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-110
- Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
- Verduijn M, 2011, NEPHROL DIAL TRANSPL, V26, P56, DOI 10.1093/ndt/gfq661
- Viaene L, 2013, NEPHROL DIAL TRANSPL, V28, P3024, DOI 10.1093/ndt/gft039
- Vittinghoff E, 2007, AM J EPIDEMIOL, V165, P710, DOI 10.1093/aje/kwk052
- Wesseling-Perry K, 2013, BONE, V54, P222, DOI 10.1016/j.bone.2012.10.008
- Zhu DX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019595